Arch Venture Partners Xii, Llc - Net Worth and Insider Trading
Arch Venture Partners Xii, Llc Net Worth
The estimated net worth of Arch Venture Partners Xii, Llc is at least $127 Million dollars as of 2024-05-08. Arch Venture Partners Xii, Llc is the 10% Owner of Prime Medicine Inc and owns about 15,456,594 shares of Prime Medicine Inc (PRME) stock worth over $86 Million. Arch Venture Partners Xii, Llc is also the 10% Owner of Neumora Therapeutics Inc and owns about 4,131,207 shares of Neumora Therapeutics Inc (NMRA) stock worth over $41 Million. Details can be seen in Arch Venture Partners Xii, Llc's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Arch Venture Partners Xii, Llc has not made any transactions after 2024-02-15 and currently still holds the listed stock(s).
Transaction Summary of Arch Venture Partners Xii, Llc
Arch Venture Partners Xii, Llc Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Arch Venture Partners Xii, Llc owns 1 companies in total, including Neumora Therapeutics Inc (NMRA) .
Click here to see the complete history of Arch Venture Partners Xii, Llc’s form 4 insider trades.
Insider Ownership Summary of Arch Venture Partners Xii, Llc
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| NMRA | Neumora Therapeutics Inc | 2023-11-14 | 10 percent owner |
Arch Venture Partners Xii, Llc Latest Holdings Summary
Arch Venture Partners Xii, Llc currently owns a total of 2 stocks. Among these stocks, Arch Venture Partners Xii, Llc owns 15,456,594 shares of Prime Medicine Inc (PRME) as of February 15, 2024, with a value of $86 Million and a weighting of 67.97%. Arch Venture Partners Xii, Llc also owns 4,131,207 shares of Neumora Therapeutics Inc (NMRA) as of November 14, 2023, with a value of $41 Million and a weighting of 32.03%.
Latest Holdings of Arch Venture Partners Xii, Llc
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| PRME | Prime Medicine Inc | 2024-02-15 | 15,456,594 | 5.57 | 86,093,229 |
| NMRA | Neumora Therapeutics Inc | 2023-11-14 | 4,131,207 | 9.82 | 40,568,453 |
Holding Weightings of Arch Venture Partners Xii, Llc
Arch Venture Partners Xii, Llc Form 4 Trading Tracker
According to the SEC Form 4 filings, Arch Venture Partners Xii, Llc has made a total of 1 transactions in Prime Medicine Inc (PRME) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Prime Medicine Inc is the acquisition of 3,200,000 shares on February 15, 2024, which cost Arch Venture Partners Xii, Llc around $20 Million.
According to the SEC Form 4 filings, Arch Venture Partners Xii, Llc has made a total of 6 transactions in Neumora Therapeutics Inc (NMRA) over the past 5 years, including 6 buys and 0 sells. The most-recent trade in Neumora Therapeutics Inc is the acquisition of 35,010 shares on November 14, 2023, which cost Arch Venture Partners Xii, Llc around $412,068.
Insider Trading History of Arch Venture Partners Xii, Llc
- 1
Arch Venture Partners Xii, Llc Trading Performance
GuruFocus tracks the stock performance after each of Arch Venture Partners Xii, Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Arch Venture Partners Xii, Llc is 36.42%. GuruFocus also compares Arch Venture Partners Xii, Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Arch Venture Partners Xii, Llc within 3 months outperforms 6 times out of 7 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Arch Venture Partners Xii, Llc's insider trading performs compared to the benchmark.
Performance of Arch Venture Partners Xii, Llc
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 2.17 |  | | | | |
| Relative Return to S&P 500(%) | 1.51 | | | | | |
Arch Venture Partners Xii, Llc Ownership Network
Arch Venture Partners Xii, Llc Owned Company Details
What does Neumora Therapeutics Inc do?
Who are the key executives at Neumora Therapeutics Inc?
Arch Venture Partners Xii, Llc is the 10 percent owner of Neumora Therapeutics Inc. Other key executives at Neumora Therapeutics Inc include director & 10 percent owner Kristina Burow , director & President & CEO Henry O Gosebruch , and 10 percent owner Amgen Inc .
Neumora Therapeutics Inc (NMRA) Insider Trades Summary
Over the past 18 months, Arch Venture Partners Xii, Llc made 6 insider transaction in Neumora Therapeutics Inc (NMRA) with a net purchase of 507,064. Other recent insider transactions involving Neumora Therapeutics Inc (NMRA) include a net purchase of 2,007,064 shares made by Kristina Burow , a net purchase of 1,764,705 shares made by Amgen Inc , and a net purchase of 1,500,000 shares made by Arch Venture Partners X, Llc .
In summary, during the past 3 months, insiders sold 0 shares of Neumora Therapeutics Inc (NMRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Neumora Therapeutics Inc (NMRA) were sold and 7,293,833 shares were bought by its insiders, resulting in a net purchase of 7,293,833 shares.
Neumora Therapeutics Inc (NMRA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Neumora Therapeutics Inc Insider Transactions
Arch Venture Partners Xii, Llc Mailing Address
Above is the net worth, insider trading, and ownership report for Arch Venture Partners Xii, Llc. You might contact Arch Venture Partners Xii, Llc via mailing address: 8755 W Higgins Road, Suite 1025, Chicago Il 60631.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
